A comprehensive new review published in the World Journal of Pediatrics has systematically evaluated the evidence linking CHD family proteins to cardiac development, revealing that these chromatin remodelers have distinct, stage-specific roles. The study, led by a team from China, synthesizes findings from human genetics, animal models, and stem-cell systems to create a working model that assigns specific functions to CHD7, CHD4, and CHD8 during heart formation. This framework not only clarifies the molecular underpinnings of congenital heart defects but also provides actionable guidance for clinical genetic screening and future therapeutic development.
CHD7, the gene most frequently mutated in CHARGE syndrome, plays a dominant role in early morphogenetic events that build the heart's structure. In contrast, CHD3 and CHD4 act as "identity guardians" during chamber formation, ensuring that heart cells commit to the correct fate. For CHD8, emerging evidence points to its regulation of later ventricular growth and functional maturation. The review emphasizes that these proteins act at different developmental stages—CHD7 early, CHD4 mid, and CHD8 late—but notes that direct proof of their coordinated action is lacking. To guide future research, the authors propose three testable models: parallel, sequential, and compensatory, each offering a different view of how these remodelers might cooperate or buffer each other's loss.
The findings have direct clinical implications. For genetic screening, the study provides clear prioritization: CHD7 for outflow-tract defects, CHD4 for chamber-patterning anomalies, and CHD8 for ventricular dysfunction. This prioritization can improve diagnostic efficiency by narrowing the search space. Therapeutically, while directly targeting remodelers is risky due to their broad expression, identifying their downstream pathways—such as those regulating cardiomyocyte proliferation or metabolism—may offer safer drug targets. Future studies combining time-resolved multi-omics and combinatorial genetics could uncover how these proteins coordinate across development, potentially paving the way for precise, temporally controlled epigenetic therapies.
The review's key contribution is its systematic analysis of the evidence, which reveals a clear division of labor among CHD proteins. "The data show that we cannot treat these proteins as a single, interchangeable group. They have very distinct, stage-specific jobs," the authors said. "For example, CHD7 is the key player in the early morphogenetic events that build the heart's structure, while CHD4 helps lock in the identity of heart cells as they differentiate. This refined view points us toward which specific gene to look at when studying different types of heart defects, and it opens the door to asking whether these remodelers work together or buffer each other's loss."
The review, available at DOI: 10.1007/s12519-026-01049-y, was supported by several Chinese funding bodies, including the National Key Research and Development Program of China and the National Natural Science Foundation of China.
